Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
A0A1W2PPD8
UPID:
KDM4F_HUMAN
Alternative names:
-
Alternative UPACC:
A0A1W2PPD8
Background:
The Probable lysine-specific demethylase 4F plays a pivotal role in epigenetic regulation through its probable histone demethylase activity, specifically targeting 'Lys-9' of histone H3. This action is crucial in the dynamic modulation of histone code, influencing gene expression and chromatin structure.
Therapeutic significance:
Understanding the role of Probable lysine-specific demethylase 4F could open doors to potential therapeutic strategies. Its involvement in the precise regulation of gene expression through histone modification highlights its potential as a target in epigenetic therapy.